What is Ability Pharmaceuticals?
Ability Pharmaceuticals, established in 2009 and headquartered in Catalonia, Spain, is a clinical-stage biopharmaceutical company dedicated to pioneering novel oncology treatments. The company is advancing two key drug candidates: ABTL0812, currently in Phase 2 clinical trials, and ABTL0815, in preclinical development. This strategic focus positions Ability Pharmaceuticals as a notable player within the Spanish and Catalan biotech landscape. A significant territorial license agreement for ABTL0812 was established in April 2016 with SciClone Pharmaceuticals, Inc. for the Greater China market, highlighting the company's global ambitions and the recognized potential of its therapeutic pipeline.
How much funding has Ability Pharmaceuticals raised?
Ability Pharmaceuticals has raised a total of $7.6M across 1 funding round:
Other Financing Round
$7.6M
Other Financing Round (2024): $7.6M with participation from The CDTI, Inveready, CTI Life Sciences Fund, and The European Innovation Council
Key Investors in Ability Pharmaceuticals
The CDTI
The CDTI is a Spanish government agency that supports innovation and offers public aid for research and development projects, playing a crucial role in fostering technological advancement within Spanish companies.
Inveready
Inveready is a Spanish financial services firm specializing in investment solutions and wealth management, actively investing in small and mid-market segments with a focus on sustainable growth.
CTI Life Sciences Fund
CTI Life Sciences Fund is a Canadian venture capital firm dedicated to transforming innovative biotech assets into scalable companies, with a strategic focus on oncology and other therapeutic areas.
What's next for Ability Pharmaceuticals?
With the recent influx of capital, Ability Pharmaceuticals is poised to accelerate the development and clinical progression of its promising oncology pipeline. The enterprise-level funding will likely support the advancement of ABTL0812 through its ongoing trials and further the preclinical research for ABTL0815. This strategic investment is expected to bolster the company's research and development capabilities, potentially enabling expansion into new markets and therapeutic areas. The backing from key investors suggests confidence in Ability Pharmaceuticals' innovative approach to addressing unmet medical needs in cancer treatment, paving the way for future growth and potential commercialization.
See full Ability Pharmaceuticals company page
